No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for enGene Holdings Inc. (ENGN) stock was $1.83 as of Oct 6, 2026, 10:05 AM EDT, down 2.41% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -75.7%
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm.
Biotechnology · Montreal, QC
Next Earnings Date
Dec 28, 2026
83 days away
EPS Estimate
-0.46
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.47
vs Estimate
$-0.43
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ENGN | $122.26M | $1.82 | -2.41% | -75.71% | N/A | N/A | N/A |
| 2CBUS | $122.89M | $1.61 | -4.17% | +16.58% | -59.70% | N/A | vs ENGN |
| 3HURA | $120.68M | $1.90 | +1.34% | -27.96% | -45.49% | -52.09% | vs ENGN |
| 4IMDX | $120.28M | $3.73 | +1.50% | +9.50% | -44.39% | -29.11% | vs ENGN |
| 5GNLX | $118.38M | $2.64 | +1.54% | -41.42% | N/A | N/A | vs ENGN |
| 6CRBU | $118.02M | $1.19 | N/A | -47.42% | -44.43% | N/A | vs ENGN |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 7 analysts
Average Price Target
$3.29
+80.0% upside
Low
$2.00
Current
$1.82
High
$5.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $-0.55 | $-0.46 | $-0.39 | 5 |
| Quarter ending Jan 2027 | $-0.34 | $-0.34 | $-0.34 | 2 |
| Quarter ending Apr 2027 | $-0.31 | $-0.31 | $-0.31 | 1 |
| Quarter ending Jul 2027 | $-0.29 | $-0.29 | $-0.29 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.89 | $-1.81 | $-1.73 | 6 |
| FY 2027 | $-1.91 | $-1.45 | $-1.02 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Oct 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jan 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Apr 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jul 2027 | $2.37M | $2.37M | $2.37M | 1 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $3.80M | $4.78M | $5.77M | 8 |
| FY 2027 | $5.53M | $6.97M | $8.41M | 5 |
